![]() |
產(chǎn)地 | 進(jìn)口、國產(chǎn) |
品牌 | 上海莼試 |
保存條件 | Store at -20 °C |
貨號 | CS12270 |
應(yīng)用范圍 | WB=1:100-500 ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500 |
CAS編號 | |
抗體名 | Anti-SRRM1 |
克隆性 | 是 |
靶點(diǎn) | 詳見說明書 |
適應(yīng)物種 | 詳見說明書 |
形態(tài) | 詳見說明書 |
宿主 | 詳見說明書 |
亞型 | IgG |
標(biāo)識物 | 詳見說明書 |
濃度 | 1mg/1ml% |
免疫原 | KLH conjugated synthetic peptide derived from human SRRM1 |
產(chǎn)品訂購信息:
英文名稱 Anti-SRRM1
中文名稱 絲氨酸/精氨酸相關(guān)核基質(zhì)蛋白1抗體規(guī)格
別 名 Ser/Arg related nuclear matrix protein; Ser/Arg-related nuclear matrix protein; Serine/arginine repetitive matrix protein 1; SR related nuclear matrix protein of 160 kDa; SR-related nuclear matrix protein of 160 kDa; SRm160; Srrm1; SRRM1_HUMAN.
濃 度 1mg/1ml
規(guī) 格 0.2ml/200μg
抗體來源 Rabbit
克隆類型 polyclonal
交叉反應(yīng) Human, Mouse, Rat, Chicken, Dog, Pig, Cow, Rabbit
產(chǎn)品類型 一抗
研究領(lǐng)域 細(xì)胞生物 染色質(zhì)和核信號 表觀遺傳學(xué)
蛋白分子量 predicted molecular weight: 102kDa
性 狀 Lyophilized or Liquid
免 疫 原 KLH conjugated synthetic peptide derived from human SRRM1
亞 型 IgG
純化方法 affinity purified by Protein A
儲 存 液 Preservative: 15mM Sodium Azide, Constituents: 1% BSA, 0.01M PBS, pH 7.4
絲氨酸/精氨酸相關(guān)核基質(zhì)蛋白1抗體規(guī)格 產(chǎn)品應(yīng)用 WB=1:100-500 ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500
(石蠟切片需做抗原修復(fù))
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
保存條件 Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
Important Note This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
產(chǎn)品介紹 Part of pre- and post-splicing multiprotein mRNP complexes. Involved in numerous pre-mRNA processing events. Promotes constitutive and exonic splicing enhancer (ESE)-dependent splicing activation by bridging together sequence-specific (SR family proteins, SFRS4, SFRS5 and TRA2B/SFRS10) and basal snRNP (SNRP70 and SNRPA1) factors of the spliceosome. Stimulates mRNA 3'-end cleavage independently of the formation of an exon junction complex. Binds both pre-mRNA and spliced mRNA 20-25 nt upstream of exon-exon junctions. Binds RNA and DNA with low sequence specificity and has similar preference for either double- or single-stranded nucleic acid substrates.
Function : Part of pre- and post-splicing multiprotein mRNPcomplexes. Involved in numerous pre-mRNA processing events.Promotes constitutive and exonic splicing enhancer (ESE)-dependentsplicing activation by bridging together sequence-specific (SRfamily proteins, SFRS4, SFRS5 and TRA2B/SFRS10) and basal snRNP(SNRP70 and SNRPA1) factors of the spliceosome. Stimulates mRNA3'-end cleavage independently of the formation of an exon junctioncomplex. Binds both pre-mRNA and spliced mRNA 20-25 nt upstream ofexon-exon junctions. Binds RNA and DNA with low sequencespecificity and has similar preference for either double- orsingle-stranded nucleic acid substrates.
Subunit : Identified in the spliceosome C complex. Found in apre-mRNA splicing complex with SFRS4, SFRS5, SNRP70, SNRPA1, SRRM1and SRRM2. Found in a pre-mRNA exonic splicing enhancer (ESE)complex with SNRP70, SNRPA1, SRRM1 and TRA2B/SFRS10. Found in amRNA splicing-dependent exon junction complex (EJC) with DEK,PRPF8, NCBP1, RBM8A, RNPS1, SRRM1 and ALYREF/THOC4. Interacts withBAT1, CPSF1, RBM8A, RNPS1, and ALYREF/THOC4. Seems to be a compoundof RNA export complexes that are released from speckles in aATP-dependent manner.
Subcellular Location : Nucleus matrix. Nucleus speckle.
Similarity : Belongs to the splicing factor SR family.
Contains 1 PWI domain.
Database links : UniProtKB/Swiss-Prot: Q8IYB3.2
轉(zhuǎn)錄輔助因子退變樣蛋白4 多克隆抗體 VGLL4 Polyclonal Antibody 700/30ul#1540/100ul#2520/200ul
溶質(zhì)載體家族17(依賴無機(jī)磷酸協(xié)同轉(zhuǎn)運(yùn)蛋白)成員6 多克隆抗體 VGLU2 Polyclonal Antibody 700/30ul#1540/100ul#2520/200ul
vonHippel-Lindau抑制因子 多克隆抗體 VHL Polyclonal Antibody 700/30ul#1540/100ul#2520/200ul
極受體 多克隆抗體 VLDLR Polyclonal Antibody 700/30ul#1540/100ul#2520/200ul
波形蛋白IF關(guān)聯(lián)卷曲螺旋蛋白 多克隆抗體 VMAC Polyclonal Antibody 700/30ul#1540/100ul#2520/200ul
自噬相關(guān)蛋白12抗體 孕激素受體抗體
自噬相關(guān)蛋白13抗體 孕激素受體β(MPRβ)抗體
自噬相關(guān)蛋白3抗體 閱讀障礙相關(guān)蛋白DLX2抗體
G1氨基A型受體相似蛋白2抗體 遠(yuǎn)端上游元件結(jié)合蛋白3抗體
整合素樣金屬蛋白酶與凝血酶4型抗體 原纖維蛋白2抗體
新朊蛋白抗體 CWF19L1蛋白抗體
SHISA蛋白家族9抗體 CWC22蛋白抗體
固醇攜帶蛋白2抗體 CUTL1蛋白抗體
唾液酸結(jié)合性免疫球蛋白樣凝集素1抗體 CULLIN抗體
SPOP蛋白抗體 Cullin3抗體
棉籽Cotton seed Raffinose 棉子糖 512-69-6 C18H32O16 ≥98%
川陳皮速NobilqtinHPLC≥98%;20mg/支
7-去甲基銀杏雙黃同;7-去甲基銀杏雙黃同;果素 7-去甲基銀杏雙黃同 Bilobetin 521-32-4 20mg HPLC≥98% 用于含量測定
中藥對照藥材雄蠶蛾(家蠶)121457-200501TLC法鑒別
Ginkgolic Acid (C15:1)銀杏酸(C15:1)純度:≥99%
絲氨酸/精氨酸相關(guān)核基質(zhì)蛋白1抗體規(guī)格云南紅豆杉Taxus yunnanensis Taxiresinol 紫杉脂素 40951-69-7 C19H22O6 ≥97%
月桂氮卓同Lcuroccprcm297-89-30.1ml
蘆薈苷;蘆薈甙;蘆薈大黃素甙;蘆薈素 Aloin 1415-73-2 20mg HPLC≥98% 用于含量測定
對照品他唑巴坦130511-200402含量測定
大花雙參苷A iplostoside A 20mg HPLC≥98% 大花雙參苷A用于含量測定
抗體的生物素化標(biāo)記實(shí)驗(yàn)要點(diǎn):
1. 絲氨酸/精氨酸相關(guān)核基質(zhì)蛋白1抗體規(guī)格 如在反應(yīng)混合液中有疊氮鈉或游離氨基存在,會抑制標(biāo)記反應(yīng)。因此,蛋白質(zhì)在反應(yīng)前要對 0.1mol/L碳酸氫鈉緩沖液或0.5mol/L硼酸緩沖液充分透析;
2.所用的NHSB及待生物素化蛋白質(zhì)之間的分子比按蛋白質(zhì)表面的ε-氨基的密度會有所不同,選擇不當(dāng)則影響標(biāo)記的效率,應(yīng)先用幾個不同的分子比來篩選最適條件;
3.用NHSB量過量也是不利的,抗原的結(jié)合位點(diǎn)可能因此被封閉,導(dǎo)致抗體失活;
4.由于抗體的氨基不易接近可能造成生物素化不足,此時可加入去污劑如 Triton x-100, Tween20等;
5.當(dāng)游離ε-氨基(賴氨酸殘基的氨基)存在于抗體的抗原結(jié)合位點(diǎn)時,或位于酶的催化位點(diǎn)時,生物素化會降低或損傷抗體蛋白的結(jié)合力或活性;
6.生物素還可能與不同的功能基團(tuán),如羰基、氨基、巰基、異咪唑基及苯酚基,也可與糖基共價結(jié)合;
7.交聯(lián)反應(yīng)后,應(yīng)充分透析,否則,殘余的生物素會對生物素化抗體與親和素的結(jié)合產(chǎn)生競爭作用;
8.在細(xì)胞的熒光標(biāo)記實(shí)驗(yàn)中,中和親和素的本底低,但由于鏈霉親和素含有少量正電荷,故對某些細(xì)胞可導(dǎo)致高本底。
抗體的鑒定:
1)絲氨酸/精氨酸相關(guān)核基質(zhì)蛋白1抗體規(guī)格 抗體的效價鑒定:不管是用于診斷還是用于,制備抗體的目的都是要求較高效價。不同的抗原制備的抗體,要求的效價不一。鑒定效價的方法很多,包括有試管凝集反應(yīng),瓊脂擴(kuò)散試驗(yàn),酶聯(lián)免疫吸附試驗(yàn)等。常用的抗原所制備的抗體一般都有約成的鑒定效價的方法,以資比較。如制備抗抗體的效價,一般就采用瓊脂擴(kuò)散試驗(yàn)來鑒定。
2)抗體的特異性鑒定:抗體的特異性是指與相應(yīng)抗原或近似抗原物質(zhì)的識別能力??贵w的特異性高,它的識別能力就強(qiáng)。衡量特異性通常以交叉反應(yīng)率來表示。交叉反應(yīng)率可用競爭抑制試驗(yàn)測定。以不同濃度抗原和近似抗原分別做競爭抑制曲線,計(jì)算各自的結(jié)合率,求出各自在IC50時的濃度,并按公式計(jì)算交叉反應(yīng)率。
如果所用抗原濃度IC50濃度為pg/管,而一些近似抗原物質(zhì)的IC50濃度幾乎是無窮大時,表示這一抗血清與其他抗原物質(zhì)的交叉反應(yīng)率近似為0,即該血清的特異性較好。
3)抗體親和力:是指抗體和抗原結(jié)合的牢固程度。親和力的高低是由抗原分子的大小,抗體分子的結(jié)合位點(diǎn)與抗原決定簇之間立體構(gòu)型的合適度決定的。有助于維持抗原抗體復(fù)合物穩(wěn)定的分子間力有氫鍵,疏水鍵,側(cè)鏈相反電荷基因的庫侖力,范德華力和空間斥力。親和力常以親和常數(shù)K表示,K的單位是L/mol。抗體親和力的測定對抗體的篩選,確定抗體的用途,驗(yàn)證抗體的均一性等均有重要意義。